As such, several clinical trials for Alzheimer's disease drugs already stratifytheir cohorts by APOE genotype — a major risk gene for AD that may havea bearing on treatment response as well as disease risk (see Riedel et al., submitted forpublication, for a review of APOE effects, which are remarkably complex). This evidence concerns the gene APOE and early-onset autosomal dominant Alzheimer disease.